Long intergenic noncoding RNA smad7 (Linc-smad7) promotes the epithelial-mesenchymal transition of HCC by targeting the miR-125b/SIRT6 axis

被引:13
作者
Han, Lili [1 ]
Jia, Lijun [1 ]
Zan, Ying [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Coll Med, Dept Oncol, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
HEPATOCELLULAR-CARCINOMA; SIRT6; CANCER; OSTEOSARCOMA; MECHANISMS; EXPRESSION; MIGRATION; INVASION; CELLS;
D O I
10.1002/cam4.3515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Long intergenic noncoding RNA smad7 (Linc-smad7) has been recently identified as a new long non-coding RNA (lncRNA). However, the role of Linc-smad7 in the tumourigenesis of human cancers remains unknown. This study uncovered that Linc-smad7 was increased in HCC samples and HCC cell lines using RT-qPCR assays. Furthermore, the overexpression of Linc-smad7 indicated poor clinicopathological features and outcomes for HCC patients. In addition, Linc-smad7 promoted HCC cells proliferation, migration, invasion and EMT, as determined by MTT, colony formation, Transwell assays and western blot analysis. Functionally, it was demonstrated that Linc-smad7 could bind with microRNA-125b (miR-125b), and the restoration of miR-125b rescued the promoting effects of Linc-smad7 on HCC cells. Finally, it was observed that sirtuin 6 (SIRT6) was positively regulated by Linc-smad7 in HCC as the direct target of miR-125b, and decreased SIRT6 reversed the effects of Linc-smad7 on promoting HCC. In conclusion, the current study first identified Linc-smad7 is increased in HCC, facilitating HCC cells proliferation, migration, invasion and EMT via regulating the miR-125b/SIRT6 axis.
引用
收藏
页码:9123 / 9137
页数:15
相关论文
共 46 条
[1]   Transforming growth factor-β-induced lncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC(A) cells [J].
Arase, Mayu ;
Horiguchi, Kana ;
Ehata, Shogo ;
Morikawa, Masato ;
Tsutsumi, Shuichi ;
Aburatani, Hiroyuki ;
Miyazono, Kohei ;
Koinuma, Daizo .
CANCER SCIENCE, 2014, 105 (08) :974-982
[2]   Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents [J].
Cagnetta, Antonia ;
Soncini, Debora ;
Orecchioni, Stefania ;
Talarico, Giovanna ;
Minetto, Paola ;
Guolo, Fabio ;
Retali, Veronica ;
Colombo, Nicoletta ;
Carminati, Enrico ;
Clavio, Marino ;
Miglino, Maurizio ;
Bergamaschi, Micaela ;
Nahimana, Aimable ;
Duchosal, Michel ;
Todoerti, Katia ;
Neri, Antonino ;
Passalacqua, Mario ;
Bruzzone, Santina ;
Nencioni, Alessio ;
Bertolini, Francesco ;
Gobbi, Marco ;
Lemoli, Roberto M. ;
Cea, Michele .
HAEMATOLOGICA, 2018, 103 (01) :80-90
[3]   Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells [J].
Cea, Michele ;
Cagnetta, Antonia ;
Adamia, Sophia ;
Acharya, Chirag ;
Tai, Yu-Tzu ;
Fulciniti, Mariateresa ;
Ohguchi, Hiroto ;
Munshi, Aditya ;
Acharya, Prakrati ;
Bhasin, Manoj K. ;
Zhong, Lei ;
Carrasco, Ruben ;
Monacelli, Fiammetta ;
Ballestrero, Alberto ;
Richardson, Paul ;
Gobbi, Marco ;
Lemoli, Roberto M. ;
Munshi, Nikhil ;
Hideshima, Teru ;
Nencioni, Alessio ;
Chauhan, Dharminder ;
Anderson, Kenneth C. .
BLOOD, 2016, 127 (09) :1138-1150
[4]   Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells [J].
Chen, Wei ;
Wang, Huizhi ;
Liu, Yawen ;
Xu, Wei ;
Ling, Chen ;
Li, Yafang ;
Liu, Junqiang ;
Chen, Mengjiao ;
Zhang, Youli ;
Chen, Baoding ;
Gong, Aihua ;
Xu, Min .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2020, 121 (01) :632-641
[5]   miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A [J].
Chen, Yi-Fen ;
Wei, Yun-Yen ;
Yang, Cheng-Chieh ;
Liu, Chung-Ji ;
Yeh, Li-Yin ;
Chou, Chung-Hsien ;
Chang, Kuo-Wei ;
Lin, Shu-Chun .
REDOX BIOLOGY, 2019, 22
[6]   Regulatory networks defining EMT during cancer initiation and progression [J].
De Craene, Bram ;
Berx, Geert .
NATURE REVIEWS CANCER, 2013, 13 (02) :97-110
[7]   Long non-coding RNAs: new players in cell differentiation and development [J].
Fatica, Alessandro ;
Bozzoni, Irene .
NATURE REVIEWS GENETICS, 2014, 15 (01) :7-21
[8]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Llovet, Josep M. ;
Bruix, Jordi .
LANCET, 2012, 379 (9822) :1245-1255
[9]   Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies [J].
Galun, Danijel ;
Srdic-Rajic, Tatjana ;
Bogdanovic, Aleksandar ;
Loncar, Zlatibor ;
Zuvela, Marinko .
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2017, 4 :93-103
[10]  
Gao H, 2019, J CELL PHYSL, V20